In what could become the first major breakthrough in the treatment of the most deadly and disabling form of stroke, doctors reported today that a hemophilia drug substantially reduced death, disability and bleeding in the brains of patients. Doctors at the UW-Madison and the Medical College of Wisconsin say they hope to get the drug into an upcoming phase 3 trial, needed for FDA approval.
Office of Strategic Communication